Status: Recruiting
Zhibitai Capsules for the Treatment of Primary Hyperlipidemia
Exploring the benefit risk ratio of increase in dosage of Zhibitai capsules (2 capsules at a time, 2 times a day) compared to the original dosage (1 capsule at a time, 1 day)
Participants needed: 192
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Chengdu Diao Jiuhong Pharmaceutical FactoryUpdated: Nov 20, 2025Locations: 1
Eligibility criteria
Age between 18 and 75 years old (inclusive), regardless of gender; [+6]
Known or suspected allergy to any component of the investigational product, or h... [+25]